Mario O. U.
- Country
- France
- Department
- Hématologie
Research Overview
- Efficacy of Venetoclax Plus Cytarabine Versus Idarubicin Plus Cytarabine in Post-Remission Therapy for Elderly Patients with Acute Myeloid Leukemia
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
- Phase II Multicenter Study of Ivosidenib in IDH1-Mutated Myelodysplastic Syndrome Patients
Data & Insights
Has run more than one trial at 38 of 133 partner sites.
Specializations
Myelodysplastic Syndrome Research
The investigator specializes in treating myelodysplastic syndrome with specific focus on genetic mutations. Their work encompasses targeted therapies for patients with IDH1 and IDH2 mutations, exploring innovative treatment approaches for this hematologic condition.
- Mutation-specific treatments
- Treatment response evaluation
- Targeted therapeutic approaches
Acute Myeloid Leukemia Expertise
The investigator conducts extensive research in acute myeloid leukemia treatment across different age groups. Their work includes evaluation of various therapeutic combinations including venetoclax, cytarabine, and innovative formulations like CPX-351.
- Age-specific treatment protocols
- Novel drug combinations
- Risk-stratified approaches
Myelofibrosis Studies
The investigator is involved in developing new therapeutic strategies for myelofibrosis, particularly focusing on combination treatments involving selective inhibitors of nuclear export with established therapies.
- Treatment-naïve patient care
- Combination therapy assessment
- Novel therapeutic pathways
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.